Sanagapalli, S.Ko, Y.Kariyawasam, V.Ng, S.C.Tang, W.de Silva, H.J.Chen, M.Wu, K.Aniwan, S.Ng, K.K.Ong, D.Ouyang, Q.Hilmi, I.Simadibrata, M.Pisespongsa, P.Gopikrishna, S.Leong, R.W.IBD Sydney Organization and the asia-Pacific Crohn's Epidemiology Study (ACCESS) Group2019-01-032019-01-032018Intestinal Research. 2018;16(3): 409-4152288-1956 (Electronic)1598-9100 (Print)1598-9100 (Linking)http://repository.kln.ac.lk/handle/123456789/19267Indexed in Scopus; In PUBMED; Indexed in MEDLINEBACKGROUND/AIMS: To examine the association between use of oral contraceptive pills (OCPs) and the risk of developing inflammatory bowel diseases (IBD), in a modern cohort. METHODS: A prospective nested case-control study across sites in the Asia-Pacific region was conducted; involving female IBD cases and asymptomatic controls. Subjects completed a questionnaire addressing questions related to OCP use. Primary outcome was the risk of development of IBD of those exposed to OCP versus non-exposure. Secondary outcomes were development of Crohn's disease (CD) versus ulcerative colitis (UC), and whether age of first use of OCP use may be associated with risk of IBD. RESULTS: Three hundred and forty-eight female IBD cases (41% CD, median age: 43 years) and 590 female age-matched controls were recruited. No significant association was found between OCP use and the risk of IBD (odds ratio [OR], 1.65; 95% confidence interval, 0.77-3.13; P=0.22), CD (OR, 1.55) or UC (OR, 1.01). The lack of association persisted when results were adjusted for age and smoking. IBD cases commenced OCP use at a younger age than controls (18 years vs. 20 years, P=0.049). CONCLUSIONS: In this large cohort of subjects from the Asia-Pacific region, we found a modest but not significantly increased risk of developing IBD amongst OCP users.en-USInflammatory Bowel DiseasesContraceptive AgentsContraceptive Agents, HormonalContraceptives, OralContraceptives, Oral-adverse effectsArticle